$0.27 EPS Expected for Myriad Genetics (MYGN) This Quarter

Analysts predict that Myriad Genetics (NASDAQ:MYGN) will announce earnings per share (EPS) of $0.27 for the current quarter, Zacks reports. Five analysts have made estimates for Myriad Genetics’ earnings. The lowest EPS estimate is $0.26 and the highest is $0.28. Myriad Genetics also reported earnings of $0.27 per share in the same quarter last year. The firm is scheduled to announce its next quarterly earnings results on Tuesday, May 1st.

According to Zacks, analysts expect that Myriad Genetics will report full-year earnings of $1.15 per share for the current fiscal year, with EPS estimates ranging from $1.14 to $1.17. For the next year, analysts forecast that the company will post earnings of $1.33 per share, with EPS estimates ranging from $1.09 to $1.53. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Myriad Genetics.

How to Become a New Pot Stock Millionaire

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.07. The business had revenue of $194.00 million during the quarter, compared to analysts’ expectations of $188.72 million. Myriad Genetics had a return on equity of 9.59% and a net margin of 16.67%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS.

Several equities analysts have weighed in on MYGN shares. BTIG Research started coverage on Myriad Genetics in a report on Friday, January 5th. They set a “buy” rating and a $41.00 price target for the company. Barclays restated a “hold” rating and set a $30.00 price target on shares of Myriad Genetics in a report on Monday, January 8th. ValuEngine upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 15th. Finally, Stephens set a $45.00 price target on Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $30.75.

In other news, VP Richard M. Marsh sold 13,759 shares of Myriad Genetics stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $36.25, for a total value of $498,763.75. Following the completion of the transaction, the vice president now owns 136,385 shares in the company, valued at approximately $4,943,956.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Richard M. Marsh sold 37,654 shares of Myriad Genetics stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the completion of the transaction, the vice president now owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,533 shares of company stock valued at $2,133,272. Company insiders own 6.70% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Allianz Asset Management GmbH boosted its holdings in Myriad Genetics by 4,202.5% during the 4th quarter. Allianz Asset Management GmbH now owns 485,018 shares of the company’s stock valued at $16,658,000 after acquiring an additional 473,745 shares during the period. Wells Fargo & Company MN boosted its holdings in Myriad Genetics by 98.2% during the 3rd quarter. Wells Fargo & Company MN now owns 844,339 shares of the company’s stock valued at $30,548,000 after acquiring an additional 418,335 shares during the period. Acadian Asset Management LLC boosted its holdings in Myriad Genetics by 18.4% during the 4th quarter. Acadian Asset Management LLC now owns 2,205,297 shares of the company’s stock valued at $75,743,000 after acquiring an additional 343,196 shares during the period. Bogle Investment Management L P DE purchased a new position in Myriad Genetics during the 4th quarter valued at $11,615,000. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in Myriad Genetics during the 3rd quarter valued at $9,083,000.

NASDAQ MYGN traded down $1.43 during trading on Friday, hitting $28.00. 877,916 shares of the stock traded hands, compared to its average volume of 714,849. The stock has a market capitalization of $1,955.80, a PE ratio of 26.67, a P/E/G ratio of 1.97 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.05 and a quick ratio of 1.81. Myriad Genetics has a 12-month low of $17.50 and a 12-month high of $41.57.

TRADEMARK VIOLATION WARNING: “$0.27 EPS Expected for Myriad Genetics (MYGN) This Quarter” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3341739/0-27-eps-expected-for-myriad-genetics-mygn-this-quarter.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ride My Car  Trading Up 0.7% Over Last Week
Ride My Car Trading Up 0.7% Over Last Week
Somewhat Positive News Coverage Somewhat Unlikely to Impact Nuveen Build America Bond Opp Fund  Share Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact Nuveen Build America Bond Opp Fund Share Price
Refereum Hits 1-Day Trading Volume of $1.09 Million
Refereum Hits 1-Day Trading Volume of $1.09 Million
Critical Survey: Sempra Energy  vs. Vectren
Critical Survey: Sempra Energy vs. Vectren
Critical Contrast: Brookdale Senior Living  & Healthcare Services Group
Critical Contrast: Brookdale Senior Living & Healthcare Services Group
Critical Contrast: Delek US  and The Competition
Critical Contrast: Delek US and The Competition


Leave a Reply

© 2006-2018 Ticker Report. Google+.